Introduction
Fanconi anemia (FA) is a heterogeneous genetic disorder characterized by a progressive bone marrow aplasia, chromosomal instability, and the acquisition of malignancies. The progressive bone marrow failure in FA and the late developing myeloid malignancies account for 90% of the mortality in FA 1 . Currently, the only cure for the hematopoietic manifestations of FA is HLA identical allogeneic bone marrow transplantation, a therapy available to only about 30% of patients 2 . Twelve FA complementation types (FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL and FANCM) have been identified and the cDNAs of eleven FA genes have been sequenced [3] [4] [5] [6] [7] [8] [9] [10] . The identification of these genes raises the potential of using gene transfer technology to express the functional cDNA into autologous stem cells. The bone marrow hypoplasia commonly observed in FA patients 1 and the reduced repopulating ability of stem cells in mice containing a disruption of the murine homologue of an FA gene 11, 12 led to the hypothesis that autologous, genetically-corrected, stem cells would have an engraftment and proliferation advantage. However, ex vivo culture is known to reduce stem cell engraftment in both normal murine and human cells [13] [14] [15] and in an initial phase 1 clinical trial in FA patients where myelopreparation was not routinely performed 16 the detection of transduced cells was low in all patients. Furthermore, the most efficient engraftment of transduced cells in the clinical FA trial was observed in a single patient who received non-lethal ionizing radiation. Collectively, these data provide rationale for considering nonmyeloablative therapy prior to transplantation of autologous genetically corrected stem cells.
FA cells exhibit increased chromosomal breaks in response to DNA damaging agents in vitro 3, 17 . Thus there is a theoretical potential of FA patients having an increased incidence for secondary malignancies following myelopreparation with genotoxic agents.
Due to the low frequency of FA in the general population 18 and the high incidence of malignant predisposition of FA patients, it is difficult to fully ascertain the risk associated with the genotoxic myelopreparation regimen in patients. However, several studies Interferon-gamma (IFN-γ) is a non-genotoxic immunoregulatory lymphokine with a high therapeutic index 23 that has been used to treat a number of malignancies [24] [25] [26] . Rathbun, et al. provided the first evidence that murine (Fancc -/-) and human (FANCC) hematopoietic cells were hypersensitive to IFN-γ via an increase in apoptosis 27 . These results were subsequently confirmed in an independent Fancc -/-murine model in vitro and in vivo 28, 29 . Previous work indicates that a mechanism for the hypersensitivity of FANCC deficient cells to IFN-γ is mediated by FANCC physically interacting with heat shock protein 70 to inhibit PKR activation and apoptosis 30 . Subsequent studies showed that FANCA and FANCG also participate in that complex 31 . FANCA progenitors were found to be hypersensitive to IFN-γ via an increase in apoptosis in that same study 31 .
However 
Materials and methods

Mice
The Fanca +/-and Fancg +/-lines utilized in these studies have been previously described 33, 34 .
Fanca+/-mice (C57Bl/6 x SV129), Fancg+/-, mice and Fancc+/-mice were backcrossed into a C57Bl/6J strain (CD45.2+) and then bred to generate Fanca-/-or Fancg-/-and WT mice. Congenic C57Bl/6J (CD45.2+) and B6.SJL-PtrcaPep3b/BoyJ (B6.BoyJ) mice (CD45.1+) were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained in our animal facility 12 .
Treatment and monitoring
All experimental mice were housed in the Indiana University School of Medicine Laboratory Animal Resource Center and examined regularly by one of the investigators.
Murine IFN-γ was purchased from Peprotech (Rocky Hill, NJ), reconstituted as recommended by the manufacturer, and placed within micro-osmotic pumps to administer a defined volume (0.5 µL/h for 7 days; DURECT, Cupertino, CA).
Micropumps containing either IFN-γ or phosphate-buffered saline (PBS) were implanted subcutaneously into the backs of WT, Fancc-/-, Fanca-/-, and Fancg-/-mice and removed following a 7-day infusion. IFN-γ was administered at a dosage of 0 or 400 µg/kg/day. These studies were reviewed and approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee.
Complete peripheral blood counts were obtained using an automated cell counter (Sysmex, Kobe, Japan) 7 days after treatment. The accuracy of abnormal blood counts was verified by direct examination of blood smears. Renal and hepatic functions of the mice were also examined. Spleen weight and bone marrow (BM) cellularity were
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Isolation of bone marrow
Bone marrow cells were flushed from the tibiae and femurs using Iscoves Modified Dulbecco Media (IMDM; Gibco-BRL, Gaithersburg, MD) containing 5% fetal calf serum (FCS; Hyclone Laboratories, Logan, UT). Low-density mononuclear cells (LDMNCs)
were prepared by centrifugation on ficoll-hypaque (density, 1.119; Sigma, St Louis, MO) 28 .
Hematopoietic progenitor growth
Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin agar and the solution was thoroughly mixed before plating as previously described 35 .
Growth factors used for culture of HPP-CFCs and LPP-CFCs included SCF, IL-1, M-CSF, GM-CSF, and IL-3 35 . To evaluate growth inhibitory effects of IFN-γ on progenitor cells, LDMNCs were plated in the absence or presence of IFN-γ (0.3-1 ng/mL) in clonogenic assays as described elsewhere 28 .
Evaluation of IFN-γ as a myelopreparative conditioning agent
Fancc-/-, Fanca-/-, Fancg-/-and WT mice (CD45.2+) were treated with 400 µg/kg/day of IFN-γ or PBS for 7 days as described above and then received transplants of 1 x 10 7 BM nucleated B6.BoyJ cells (CD45.1+). The percentage of CD45.1+ cells in the peripheral blood was analyzed at 1, 4, and 6 months after transplantation as described previously 11, 36 . To evaluate multilineage reconstitution of donor CD45.1+ cells, 
Statistical analyses
Computations were carried out using the Graph Pad Prism software package (San Diego, CA). Statistical comparisons among all groups were compared using analysis of variance and Student's t test. A p value less than 0.05 was considered statistically significant. 
Results
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Discussion
Though palliative therapy has improved the survival of patients with Fanconi Anemia over the past 10 years 1 , bone marrow failure remains the leading cause of death 37 .
Allogenic bone marrow transplantation or cord blood transplantation is available to a subset of these patients 2 . However, for individuals who lack an HLA compatible donor, non-HLA matched transplantation is rarely utilized because of the particularly high
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From morbidity of this therapy in FA patients 38 . Thus transplantation of genetically-corrected autologous stem cells remains an important potential therapy for this uniformly fatal disease.
In addition to the usual challenges in gene transfer protocols, FA disease itself creates an additional set of potential obstacles. Patients that are considered for gene transfer often have bone marrow hypoplasia 37 . In addition, emerging data in FA patients 39 and in For personal use only. on . by guest www.bloodjournal.org From
